- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03020329
Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Phase II Study of TPF Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: DongHua Luo, MD,PhD
- Telefonnummer: 8620-87343643
- E-post: luodh@sysucc.org.cn
Studieorter
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510060
- Rekrytering
- Sun Yat-sen University
-
Kontakt:
- HaiQiang Mai, PhD
- Telefonnummer: 8620-38606186
- E-post: maihq@sysucc.org.cn
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Patients with newly histologically confirmed non-keratinizing (according to World Health Organization (WHO) histologically type).
- Original clinical staged as T4N0-3 M0 or any T、N3M0(according to the American Joint Committee on Cancer(AJCC) 7th edition)
- No evidence of distant metastasis (M0).
- Age ≤ 18 years old.
- Satisfactory performance status: Karnofsky scale (KPS) > 70.
- Adequate marrow: leucocyte count ≥4000/μL, hemoglobin ≥90g/L and platelet count ≥100000/μL.
- Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase (AST) <1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP) ≤2.5×ULN, and bilirubin ≤ULN.
- Adequate renal function: creatinine clearance ≥60 ml/min.
- Patients must be informed of the investigational nature of this study and give written informed consent.
Exclusion Criteria:
- WHO Type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma.
- Age >18 years.
- Treatment with palliative intent.
- Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer.
- Pregnancy or lactation.
- History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume).
- Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes.
- Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose >1.5×ULN), and emotional disturbance.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Paclitaxel liposome, Cisplatin, 5-Fu,
Patients receive paclitaxel liposome(135mg/m2 on day 1), cisplatin (75mg/m2 on day 1,Separate injection on day 1 to 3) and fluorouracil (3750mg/m2 CIV 120h) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy(Intensive modulate radiotherapy,IMRT)and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
|
Patients receive paclitaxel liposome(135mg/m2 on day 1),cisplatin (75mg/m2 Separate injection on day 1 to 3) and 5-fluorouracil (3750mg/m2 CIV 120h ) every three weeks for three cycl es before the radiotherapy. Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy. Radical radiotherapy:Intensive modulate radiotherapy (IMRT),total dose for nasopharynx and nodule of neck:60Gy/30F,2.0Gy/daily.
Andra namn:
Cisplatin (75mg/m2 Separate injection on day 1 to 3) with Paclitaxel liposome and 5-fu every three weeks for three cycles before the radiotherapy.Cisplatin(100mg/m2) every three weeks for three cycles during radiotherapy.
Andra namn:
Fluorouracil (3750mg/m2 CIV 120h)with Paclitaxel liposomeand cisplatin every three weeks for three cycles before the radiotherapy.
Andra namn:
Intensive modulate radiotherapy (IMRT) will be implement,total dose for nasopharynx and nodule of neck:60Gy(Gray)/30F(Fraction),2.0Gy/daily,5 days/week.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Complete Response (CR)
Tidsram: After the completion of the chemoradiotherapy treatment (up to 9 weeks)
|
CR assessed by independent reviewers, according to the Modified Response Evaluation Criteria in Solid Tumors (RECIST) from the National Cancer Institute (NCI).
Disease response evaluated after the completion of the chemoradiotherapy treatment.
Complete response defined as the complete disappearance of the target and non-target lesion(s) identified at baseline after radiological evaluation by Magnetic Resonance Imaging (MRI) only
|
After the completion of the chemoradiotherapy treatment (up to 9 weeks)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Korttids toxiska effekter utvärderade av National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0)
Tidsram: 3 månader
|
De kortsiktiga toxiska effekterna utvärderades av National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0)
|
3 månader
|
Långtidstoxicitet
Tidsram: Genom avslutad studie, i snitt ett halvår
|
Livskvalitet utvärderades med hjälp av European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTCQLQ-C30)
|
Genom avslutad studie, i snitt ett halvår
|
Långtidstoxicitet
Tidsram: Genom avslutad studie, i snitt ett halvår
|
EORTC livskvalitet frågeformulär (QLQ) Head and Neck
|
Genom avslutad studie, i snitt ett halvår
|
Tillväxt
Tidsram: Genom avslutad studie, i snitt ett halvår
|
Patienterna kommer att övervakas för höjd (i meter)
|
Genom avslutad studie, i snitt ett halvår
|
Tillväxt
Tidsram: Genom avslutad studie, i snitt ett halvår
|
Patienterna kommer att övervakas för vikt (i kilogram)
|
Genom avslutad studie, i snitt ett halvår
|
Tillväxt
Tidsram: Genom avslutad studie, i snitt ett halvår
|
Patienterna kommer att övervakas för BMI (i kg/m^2)
|
Genom avslutad studie, i snitt ett halvår
|
Underrättelseutveckling
Tidsram: Genom avslutad studie, i snitt ett halvår
|
Intelligenskvot av Stanford-Binet test
|
Genom avslutad studie, i snitt ett halvår
|
Overall survival(OS)
Tidsram: 3-year
|
The OS was defined as the duration from the date of random assignment to the date of death from any cause or censored at the date of the last follow-up.
|
3-year
|
Progress-free survival(PFS)
Tidsram: 3-year
|
Progress-free survival is calculated from the date of randomization to the date of the first progress at any site or death from any cause or censored at the date of the last follow-up
|
3-year
|
Locoregional failure-free survival(LRFS)
Tidsram: 3-year
|
The LRFS is evaluated and calculated from the date of random assignment until the day of first locoregional relapse or until the date of the last follow-up visit
|
3-year
|
Distant metastasis-free survival(DMFS)
Tidsram: 3-year
|
The DMFS is evaluated and calculated from the date of random assignment until the day of first distant metastases or until the date of the last follow-up visit
|
3-year
|
Sex Development
Tidsram: Through study completion, an average of half year
|
Sex hormone(estrogen,testosterone) levels(in nmol/L)
|
Through study completion, an average of half year
|
Sex Development
Tidsram: Through study completion, an average of half year
|
Secondary sex characteristic survey
|
Through study completion, an average of half year
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: HaiQiang Mai, MD,PhD, Cancer center
Publikationer och användbara länkar
Allmänna publikationer
- Daoud J, Ghorbal L, Siala W, Elloumi F, Ghorbel A, Frikha M. [Is there any difference in therapeutic results of nasopharyngeal carcinoma between adults and children?]. Cancer Radiother. 2013 Dec;17(8):763-7. doi: 10.1016/j.canrad.2013.06.046. Epub 2013 Nov 20. French.
- Yan Z, Xia L, Huang Y, Chen P, Jiang L, Zhang B. Nasopharyngeal carcinoma in children and adolescents in an endemic area: a report of 185 cases. Int J Pediatr Otorhinolaryngol. 2013 Sep;77(9):1454-60. doi: 10.1016/j.ijporl.2013.06.005. Epub 2013 Jul 3.
- Liao WW, Tang SQ, Liu Y, Feng C. [Treatment of nasopharyngeal carcinoma in children]. Zhongguo Dang Dai Er Ke Za Zhi. 2013 Apr;15(4):273-6. Chinese.
- Hu S, Xu X, Xu J, Xu Q, Liu S. Prognostic factors and long-term outcomes of nasopharyngeal carcinoma in children and adolescents. Pediatr Blood Cancer. 2013 Jul;60(7):1122-7. doi: 10.1002/pbc.24458. Epub 2013 Jan 9.
- Cheuk DK, Billups CA, Martin MG, Roland CR, Ribeiro RC, Krasin MJ, Rodriguez-Galindo C. Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma. Cancer. 2011 Jan 1;117(1):197-206. doi: 10.1002/cncr.25376. Epub 2010 Aug 24.
- Buehrlen M, Zwaan CM, Granzen B, Lassay L, Deutz P, Vorwerk P, Staatz G, Gademann G, Christiansen H, Oldenburger F, Tamm M, Mertens R. Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG. Cancer. 2012 Oct 1;118(19):4892-900. doi: 10.1002/cncr.27395. Epub 2012 Feb 22.
- Shen C, Gao Y, Xu T, Wang X, Ying H, Hu C. Carcinoma of the nasopharynx in young patients: a single institution experience. Clin Oncol (R Coll Radiol). 2009 Oct;21(8):617-22. doi: 10.1016/j.clon.2009.07.005. Epub 2009 Aug 5.
- Varan A, Ozyar E, Corapcioglu F, Koksal Y, Aydin B, Yazici N, Akyuz C, Buyukpamukcu M. Pediatric and young adult nasopharyngeal carcinoma patients treated with preradiation Cisplatin and docetaxel chemotherapy. Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1116-20. doi: 10.1016/j.ijrobp.2008.05.028. Epub 2008 Sep 9.
- Laskar S, Bahl G, Muckaden M, Pai SK, Gupta T, Banavali S, Arora B, Sharma D, Kurkure PA, Ramadwar M, Viswanathan S, Rangarajan V, Qureshi S, Deshpande DD, Shrivastava SK, Dinshaw KA. Nasopharyngeal carcinoma in children: comparison of conventional and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):728-36. doi: 10.1016/j.ijrobp.2008.01.032. Epub 2008 Apr 18.
- Selek U, Ozyar E, Ozyigit G, Varan A, Buyukpamukcu M, Atahan IL. Treatment results of 59 young patients with nasopharyngeal carcinoma. Int J Pediatr Otorhinolaryngol. 2005 Feb;69(2):201-7. doi: 10.1016/j.ijporl.2004.09.001.
- Orbach D, Brisse H, Helfre S, Klijanienko J, Bours D, Mosseri V, Rodriguez J. Radiation and chemotherapy combination for nasopharyngeal carcinoma in children: Radiotherapy dose adaptation after chemotherapy response to minimize late effects. Pediatr Blood Cancer. 2008 Apr;50(4):849-53. doi: 10.1002/pbc.21372.
- Ahern V, Jenkin D, Banerjee D, Greenberg M, Payne D. Nasopharyngeal carcinoma in the young. Clin Oncol (R Coll Radiol). 1994;6(1):24-30. doi: 10.1016/s0936-6555(05)80364-4.
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter histologisk typ
- Neoplasmer
- Neoplasmer efter plats
- Neoplasmer, körtel och epitel
- Faryngeala neoplasmer
- Otorhinolaryngologiska neoplasmer
- Neoplasmer i huvud och hals
- Nasofaryngeala sjukdomar
- Faryngeala sjukdomar
- Stomatogena sjukdomar
- Otorhinolaryngologiska sjukdomar
- Nasofaryngeala neoplasmer
- Carcinom
- Nasofaryngealt karcinom
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Antimetaboliter, antineoplastiska
- Antimetaboliter
- Antineoplastiska medel
- Immunsuppressiva medel
- Immunologiska faktorer
- Tubulin modulatorer
- Antimitotiska medel
- Mitosmodulatorer
- Antineoplastiska medel, fytogena
- Paklitaxel
- Cisplatin
- Fluorouracil
- Albuminbundet paklitaxel
Andra studie-ID-nummer
- NPC in Young Patients
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Nasofaryngealt karcinom
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeOral Cavity Carcinom | Oral intraepitelial neoplasiFörenta staterna
-
Endo PharmaceuticalsAvslutad
-
Indira Gandhi Medical College, ShimlaOkänd
-
Washington University School of MedicineAvslutad
-
Stanford UniversityAvslutad
-
BayerAmgenAvslutadCarcinomFörenta staterna
-
Centre Leon BerardAvslutad
-
Ontario Clinical Oncology Group (OCOG)Avslutad
-
Yueyong XiaoOkänd
Kliniska prövningar på Paclitaxel liposome
-
Qilu Hospital of Shandong UniversityRekryteringAvancerat gastriskt eller gastroesofagealt adenokarcinomKina
-
Second Affiliated Hospital, School of Medicine,...Sun Yat-sen University; Peking University International Hospital; Zhejiang...Har inte rekryterat ännuHER2-positiv bröstcancer | HjärnmetastaserKina
-
The First Affiliated Hospital with Nanjing Medical...Har inte rekryterat ännuEsofagus skivepitelcancer
-
Institute of Nuclear Energy Research, TaiwanAvslutad
-
NCIC Clinical Trials GroupNexstar PharmaceuticalsAvslutadOspecificerad fast tumör för vuxen, protokollspecifikKanada
-
Fidia Farmaceutici s.p.a.RekryteringMajor depressiv sjukdomItalien
-
Ascension Healthcare Development LimitedRekryteringBlödarsjuka A med inhibitorRyska Federationen
-
NCIC Clinical Trials GroupAvslutadÄggstockscancer | Äggledarcancer | Peritoneal Cavity CancerKanada, Storbritannien
-
Nanfang Hospital of Southern Medical UniversityRekrytering
-
Huijing WuBeijing Xisike Clinical Oncology Research Foundation; CSPC Pharmaceutical...RekryteringAngioimmunoblastiskt T-cellslymfomKina